Background
==========

Prostate cancer, urothelial carcinoma and renal cancer are common cancer types and major cause of cancer-related death worldwide \[[@B1],[@B2]\]. Smoking, diet and environmental factors have been reported to contribute to the carcinogenesis of these malignancies \[[@B3],[@B4]\]. However, the fact that a small fraction of people exposed to these carcinogens eventually develop urinary cancers suggests that individual genetic predisposition factors may contribute to carcinogenesis.

Cytochrome P450 1B1 (*CYP1B1*) is a member of the CYP1 gene family and one of the major enzymes involved in the hydroxylation of estrogens, involved in the oxidative activation and deactivation of xenobiotics \[[@B5]-[@B7]\]. Several polymorphisms in the *CYP1B1* gene have been reported, including 4326C/G (L432V, rs1056836) in exon 3, which encodes the heme-binding domain, have been associated with enhanced catalytic activity when compared to the wild-type allele \[[@B8]-[@B10]\].

Polymorphisms in *XPC* and *MHTFR* gene have been reported to be associated with overall urinary cancer risk \[[@B11],[@B12]\], suggesting that urinary cancers share common mechanisms in the process of DNA repair and carcinogen metabolism. Several case--control studies were performed to identify the association of *CYP1B1* polymorphisms with prostate, bladder and renal cancer risk. However, small sample sizes and limited populations in study design have often yielded inclusive results among the studies \[[@B13]-[@B29]\]. The inconsistent conclusions may have resulted from difference ethnic backgrounds and relatively small sample sizes. To validate the potential association between the *CYP1B1* Leu432Val polymorphism and urinary cancer risk, we conducted a meta-analysis of data reported in 17 studies including 7,944 cases and 7,389 controls.

Methods
=======

Publication search
------------------

Medline, PubMed, Embase and Web of Science were searched for all relevant articles with the following terms: "Cytochrome P450 1B1" or "*CYP1B1*", "polymorphism" or "variant", "case--control", "risk", "association", "prostate cancer", "bladder cancer" and "renal cancer" (last search was updated on Feb 10, 2014). References of the retrieved articles on this topic were also manually screened for additional relevant eligible studies.

Selection criteria
------------------

We defined inclusion criteria as follows: written in English; case--control design; sufficient information for estimating odds ratio (OR) and their 95% confidence interval (CI); observed genotype frequencies in the controls in agreement with Hardy-Weinberg equilibrium (HWE). Abstracts and unpublished reports were not considered. Investigations in subjects with family history or cancer-prone disposition were also excluded. Meanwhile, if studies had overlapping subjects, we selected the most recent study that included the largest number of individuals in the publications. This study was approved by the ethics committee of the Second Affiliated Hospital of Nanchang University.

Data extraction
---------------

Two investigators independently extracted the following information from each study: the first author, year of publication, country of origin, ethnicity, source of controls (population-based, hospital-based and mixed controls), genotyping method, number of genotyped cases and controls, number of genotypes for three *CYP1B1* polymorphisms in cases and controls, and main findings.

Statistical methods
-------------------

Hardy--Weinberg equilibrium (HWE) was evaluated for each study, using the goodness-of-fit chi-square test. *P* \< 0.05 was considered representative of departure from HWE. Crude OR with 95% CI was used to assess the strength of association between the three *CYP1B1* L432V polymorphism and urinary cancer risk. Then, we calculated the pooled ORs and 95% CIs. Heterogeneity assumption was checked by the chi-square-based Q-test. A *P* value greater than 0.10 for the Q-test indicates a lack of heterogeneity among studies, so the pooled OR estimate of the each study was calculated by the fixed-effects model (the Mantel--Haenszel method), the random-effects model (the Der-Simonian and Laird method) was used otherwise \[[@B30],[@B31]\]. To assess the effects of individual studies on the overall risk of cancer, sensitivity analysis was performed by excluding each study at a time individually and recalculating the ORs and 95% CIs. We also used the inverted funnel plot and the Egger's test to examine the potential influence of publication bias (linear regression analysis). The significance of the intercept was determined by the t-test suggested by Egger (*P* \< 0.05 was considered representative of statistically significant publication bias) \[[@B32]\]. All statistical tests were two-sided, and a P-value of \< 0.05 was considered statistically significant. Statistical tests were performed with STATA version 11.0 (Stata Corporation, College Station, TX) or SAS software (version 9.1; SAS Institute, Cary, NC).

Results and discussion
======================

Study characteristics
---------------------

We identified a total of 71 relevant publications after initial screening. Among these, 26 publications had met the inclusion criteria and were subjected to further examination. We excluded 4 publications because they did not present detailed genotyping information. We also excluded 5 publications because they did not include L432V polymorphism. Our final data consisted of 10 publications with a total of 5949 cases and 5388 controls for prostate cancer, 5 publications with 1658 cases and 1593 controls for bladder cancer, 2 publications with 337 cases and 408 controls for renal cancer (Figure  [1](#F1){ref-type="fig"}). Of these, there were 10 hospital-based studies and 7 population-based studies. Characteristics of included studies are summarized in Table  [1](#T1){ref-type="table"}.

![The flow chart of the included studies in the meta-analysis.](1746-1596-9-113-1){#F1}

###### 

**Characteristics of studies included in the meta-analysis for an association between*CYP1B1*L432V SNP and risk of urinary cancer**

  **First author, year**     **Country**   **Ethnicity**   **Source of control**   **Cases/controls**   **MAF of controls**   **Power**^**a**^   **Source of DNA**   **Genotyping methods**
  -------------------------- ------------- --------------- ----------------------- -------------------- --------------------- ------------------ ------------------- ------------------------
  **Prostate cancer**                                                                                                                                                 
  Holt, 2013                 USA           Caucasian       PB                      1256/1235            0.41                  1                  blood               SNPlex
  Catsburg C, 2012           USA           Caucasian       PB                      1433/760             0.47                  1                  blood               Taqman
  Beuten J, 2008             USA           Caucasian       PB                      649/738              0.39                  1                  blood               Taqman
  Berndt, 2007               USA           Mixed           PB                      486/611              0.47                  1                  blood               TaqMan
  Cussenot O, 2007           France        Caucasian       HB                      1053/837             0.39                  1                  blood               TaqMan
  Sobti RC, 2006             India         Asian           PB                      100/100              0.18                  0.415              blood               PCR--RFLP
  Cicek MS, 2005             USA           Mixed           HB                      439/479              0.47                  1                  blood               PCR--RFLP
  Fukatsu, 2004              Japan         Asian           HB                      136/255              0.29                  0.947              blood               PCR--RFLP
  Chang BL, 2003             USA           Mixed           HB                      310/182              0.44                  0.807              ND                  Sequencing
  Tanaka Y, 2002             Japan         Asian           PB                      117/200              0.18                  0.857              ND                  AS-PCR
  **Bladder cancer**                                                                                                                                                  
  Berber U, 2013             Turkey        Asian           PB                      114/114              0.27                  0.499              tissue              AS-PCR
  Salinas-Sánchez AS, 2012   Spain         Caucasian       HB                      208/208              0.39                  0.875              blood               Sequencing
  Fontana L, 2009            France        Caucasian       HB                      51/45                0.58                  0.104              blood               TaqMan
  Figueroa J, 2008           Spain         Caucasian       HB                      1084/1012            0.42                  1                  blood/buccal        TaqMan
  Hung RJ, 2004              Italy         Caucasian       HB                      201/214              0.59                  0.888              ND                  PCR--RFLP
  **Renal cancer**                                                                                                                                                    
  Salinas-Sánchez AS, 2012   Spain         Caucasian       HB                      126/208              0.39                  0.875              blood               Sequencing
  Sasaki M, 2005             USA           Asian           HB                      211/200              0.18                  0.857              tissue              AS-PCR

Abbreviations: *SNP* Single nucleotide polymorphism, *HB* Hospital based, *PB* Population based, *RFLP* Restriction fragment length polymorphisms, *AS-PCR* Allele specific PCR, *ND* Not described. ^a^Statistical power to detect an OR of 1.5 (or 0.67 = 1/1.5).

Quantitative synthesis
----------------------

Table  [2](#T2){ref-type="table"} lists the main results of this meta-analysis. Overall, significant associations were found between *CYP1B1* L432V polymorphism and urinary cancer risk when all studies pooled into the meta-analysis (CC vs CG: OR = 0.937, 95% CI = 0.881-0.996; CC vs CG + GG: OR = 0.942, 95% CI = 0.890-0.997; C vs G: OR = 0.957, 95% CI = 0.917-0.998) (Figure  [2](#F2){ref-type="fig"}). In the subgroup analysis, L432V polymorphism was significantly associated with prostate cancer or overall urinary cancer risk when population was defined as only Caucasians or Asians (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). Nevertheless, when studies were restricted to population-based or hospital-based studies, none of these comparisons showed significant differences. The FPRP values for significant findings at different prior probability levels were also calculated. For a prior probability of 0.1, assuming that the OR for specific genotype was 0.67/1.50 (protection/risk), the FPRP values were 0.786, 0.79 and 0.794 for an association of overall CC vs CG, CC vs CG + GG and C vs G genotypes with an increased lung cancer risk.

###### 

**Meta-analysis of the associations between*CYP1B1*L432V polymorphism and urinary cancer risk**

  **Cancer**      **Number of studies**   **Cases/controls**   **Comparison**   **Test of association**   **Test of heterogeneity**   **Publication bias**                          
  --------------- ----------------------- -------------------- ---------------- ------------------------- --------------------------- ---------------------- ------- ------- ------ -------
  Prostate        10                      5949/5388            CC vs GG         0.942                     0.868-1.022                 0.151                  20.23   0.017   55.5   0.917
  CC vs CG        0.947                   0.881-1.018          0.137            23.13                     0.006                       61.1                   0.212                  
  CC vs CG + GG   0.952                   0.895-1.013          0.120            20.00                     0.018                       55.0                   0.671                  
  C vs G          0.963                   0.920-1.008          0.108            24.36                     0.004                       63.0                   0.723                  
  Bladder         5                       1658/1593            CC vs GG         1.061                     0.962-1.171                 0.234                  2.23    1       0.0    0.035
  CC vs CG        1.000                   0.926-1.079          0.991            7.20                      0.126                       44.4                   0.317                  
  CC vs CG + GG   1.016                   0.947-1.090          0.661            6.25                      0.181                       36.0                   0.156                  
  C vs G          1.026                   0.977-1.077          0.312            3.75                      0                           0.0                    0.060                  
  Renal           2                       337/408              CC vs GG         0.740                     0.593-0.922                 0.007                  0.73    0.394   0      \-
  CC vs CG        0.816                   0.686-0.969          0.021            1.34                      0.248                       25.2                   \-                     
  CC vs CG + GG   0.787                   0.673-0.922          0.003            1.35                      0.245                       26.0                   \-                     
  C vs G          0.818                   0.729-0.917          0.001            1.82                      0.178                       45                     \-                     
  Overall         17                      7944/7389            CC vs GG         0.941                     0.876-1.012                 0.103                  35.2    0.004   54.6   0.607
  CC vs CG        0.937                   0.881-0.996          0.037            37.29                     0.002                       57.1                   0.076                  
  CC vs CG + GG   0.942                   0.890-0.997          0.038            37.97                     0.002                       57.9                   0.199                  
  C vs G          0.957                   0.917-0.998          0.039            46.07                     0                           65.3                   0.302                  

![**Forest plot (Random effects model) describing the association of the*CYP1B1*L432V polymorphism with risk of urinary cancers.** The CC phenotype was associated with a modestly decreased risk of urinary cancers (**a**, CC vs CG; **b**, CC vs CG + GG).](1746-1596-9-113-2){#F2}

Heterogeneity and sensitivity analyses
--------------------------------------

Heterogeneities were observed among studies for the association between the *CYP1B1* L432V polymorphism and urinary cancer risk (CC vs GG, CC vs CG, CC vs CG + GG, C vs G for prostate cancer; C vs G for bladder cancer; CC vs GG, CC vs CG, CC vs CG + GG, C vs G for overall urinary cancers). Therefore, we used the random-effects model that generated wider CIs. For the other groups of comparisons, no heterogeneity was found among studies and the fixed-effects model was performed (Table  [2](#T2){ref-type="table"}, Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). The leave-one-out sensitivity analysis indicated that no single study changed the pooled ORs qualitatively (data not shown).

Publication bias
----------------

The shapes of the funnel plots seemed symmetrical, and Egger's test suggested that publication bias was only found in the CC vs GG group of bladder cancer (Table  [2](#T2){ref-type="table"}, Additional file [1](#S1){ref-type="supplementary-material"}: Table S1).

In this meta-analysis, we tested the association between L432V polymorphism in the *CYP1B1* gene and urinary cancer risk by comparing the allele frequencies from 17 published studies. We observed a significant association of L432V polymorphism with overall urinary cancer risk, as well as in the subgroups defined as Caucasian or Asian populations. Urinary system tumorigenesis is a complex event, in which different carcinogenic chemicals are involved. Prostate is a hormone-responsive organ in which androgens are believed to stimulate growth and secretory functions. Evidences have been shown that *CYP1B1* protein is highly expressed in prostate cancer tissues, while not in normal prostate tissues \[[@B33]\]. It has been reported that different allelic variants of *CYP1B1* have different catalytic activities and specificities to procarcinogens, thus partly explains molecular mechanism of *CYP1B1* in carcinogenesis \[[@B34]\]. Except for prostate cancer, case--control studies have shown inconsistent associations between *CYP1B1* L432V polymorphism and bladder cancer and renal cancer risk \[[@B24],[@B28],[@B29]\]. However, exact mechanisms of how *CYP1B1* polymorphism contributes to urinary cancer susceptibility requires further illustration.

Some limitations of this meta-analysis should be discussed. First, the total number of included studies of bladder cancer and renal cancer was relatively small. Second, our results were based on unadjusted estimates, while a more precise analysis is needed if individual data were available, which would allow for the adjustment by other factors such as age, smoking status, drinking status. Finally, unpublished data may have not been included in the current analysis, potentially causing a bias in the results.

Conclusions
===========

In conclusion, this meta-analysis suggests that the *CYP1B1* L432V polymorphism is associated with urinary cancer development, especially in specified Caucasian and Asian populations. However, studies with larger number of samples from homogeneous urinary cancer patients are needed. Further biological investigations may eventually lead to better understanding of the association between the *CYP1B1* polymorphism and urinary cancer risk.
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